Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19 Featured Image

Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19

31 Mar 20

tranScrip is pleased to note that Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19.

tranScrip continues to support Synairgen in this important endeavour, a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.

References: tranScripSynairgen

Contact our team of experts

Our physicians, scientists and service experts can help to maximise the value of your products. Whatever your project requires, we have the people to meet your needs.